Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
39 studies found for:    " November 17, 2010":" December 17, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
1 Completed Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects
Conditions: HIV;   HIV Infection
Intervention: Biological: SB-728-T
2 Completed Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX-G DNA Vaccine;   Biological: MVA-CMDR Vaccine;   Biological: Placebo PENNVAX-G Vaccine;   Biological: Placebo MVA-CMDR Vaccine
3 Completed
Has Results
Two Approaches to Routine HIV Testing in a Hospital Emergency Department
Condition: HIV Infections
Interventions: Procedure: Oral HIV screening;   Procedure: Fingerstick HIV screening
4 Completed A Randomized Controlled Trial of the Bruthas Project
Condition: HIV Infection
Interventions: Behavioral: Bruthas Project;   Behavioral: Standard HIV Testing and Counseling
5 Completed Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose
Condition: HIV Infection
Interventions: Drug: Aprepitant;   Drug: Aprepitant placebo
6 Completed Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
Condition: HIV Infection
Intervention: Biological: Fluzone®
7 Unknown  Improving Antiretroviral Medication Adherence Among HIV-infected Youth: Phase I
Condition: HIV Infection
Intervention:
8 Completed Pharmacokinetic Evaluation of Changes in Nevirapine AUC Due to Differences in Weight
Condition: HIV Infection
Intervention: Drug: Nevirapine
9 Unknown  Impact of Raltegravir on the Viral Reservoirs
Condition: HIV Infection
Intervention:
10 Completed The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)
Condition: HIV Infections
Intervention: Drug: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)
11 Unknown  Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra
Conditions: Children With Confirmed HIV Infection;   Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose;   Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment
Intervention: Drug: Mycobutin
12 Active, not recruiting Addition of Raltegravir to Established Antiretroviral Suppressive Therapy
Condition: HIV
Intervention: Drug: Raltegravir
13 Completed Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Populations Using Formula Feeding (PROMISE)
Condition: HIV
Interventions: Drug: Zidovudine (ZDV);   Drug: Nevirapine (NVP);   Drug: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]);   Drug: Lamivudine-Zidovudine (3TC-ZDV);   Drug: Lopinavir-ritonavir (LPV-RTV)
14 Withdrawn A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir
Condition: HIV
Interventions: Drug: Lopinavir;   Drug: Atazanavir
15 Active, not recruiting Modulation of Monocyte Activation by Atorvastatin in HIV Infection
Condition: HIV Dementia
Intervention: Drug: Atorvastatin
16 Completed The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER)
Conditions: HIV Infections;   Depression;   Mild Cognitive Impairment
Interventions: Drug: raltegravir single dose;   Drug: ginkgo biloba multiple dose
17 Completed Study of SystemCHANGE-HIV
Condition: HIV
Intervention: Behavioral: SystemCHANGE-HIV
18 Completed
Has Results
Effects of Growth Hormone Releasing Hormone in HIV
Conditions: HIV;   HIV Lipodystrophy
Interventions: Drug: tesamorelin;   Drug: placebo
19 Completed
Has Results
Addressing Psychosocial Needs and HIV Risk in Indian MSM
Conditions: HIV/STI Risk;   HIV/STI Incidence
Intervention: Behavioral: Behavioral intervention
20 Completed
Has Results
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
Condition: HIV-1 Infection
Interventions: Drug: FTC/RPV/TDF;   Drug: PI;   Drug: RTV;   Drug: NRTIs

   Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.